Zobrazeno 1 - 8
of 8
pro vyhledávání: '"serogroup A meningococcal conjugate vaccine"'
Autor:
Jessica R. MacNeil, Isaïe Medah, Daouda Koussoubé, Ryan T. Novak, Amanda C. Cohn, Fabien V.K. Diomandé, Denis Yelbeogo, Jean Ludovic Kambou, Tiga F. Tarbangdo, Rasmata Ouédraogo-Traoré, Lassana Sangaré, Cynthia Hatcher, Jeni Vuong, Leonard W. Mayer, Mamoudou H. Djingarey, Thomas A. Clark, Nancy E. Messonnier
Publikováno v:
Emerging Infectious Diseases, Vol 20, Iss 3, Pp 402-407 (2014)
In 2010, Burkina Faso became the first country to introduce meningococcal serogroup A conjugate vaccine (PsA-TT). During 2012, Burkina Faso reported increases in Neisseria meningitidis serogroup W, raising questions about whether these cases were a n
Externí odkaz:
https://doaj.org/article/721d162d924544658a40e15eafaddf31
Autor:
Doumagoum M. Daugla, Florence Fermon, Olivier Manigart, Jacques Toralta, Dominique A. Caugant, Cyriaque Ngadoua, Brian Greenwood, Mamoudou Harouna Djingarey, Caroline Trotter, James M. Stuart, Kadidja Gamougam, Anne-Laure Page
Publikováno v:
Emerging Infectious Diseases
Emerging Infectious Diseases, Vol 21, Iss 1, Pp 115-118 (2015)
Emerging Infectious Diseases, Vol 21, Iss 1, Pp 115-118 (2015)
In 2011, vaccination with a serogroup A meningococcal polysaccharide conjugate vaccine was implemented in 3 of 23 regions in Chad. Cases of meningitis declined dramatically in vaccinated areas, but an epidemic continued in the rest of Chad. In 2012,
Autor:
Elizabeth Kibwana, Kirsten P Perrett, Celina Jin, Ly-Mee Yu, Amy P. Winter, Tessa M. John, Nigel Curtis, Andrew J. Pollard, Elizabeth A. Clutterbuck
The maintenance of adequate serum Ab levels following immunization has been identified as the most important mechanism for individual long-term protection against rapidly invading encapsulated bacteria. The mechanisms for maintaining adequate serum A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf7c8f3b818c36500a9fc13df02657a8
https://doi.org/10.4049/jimmunol.1200451
https://doi.org/10.4049/jimmunol.1200451
Publikováno v:
Clinical Infectious Diseases. 46:e75-e77
To assess the risk of Guillain-Barré syndrome (GBS) following administration of meningococcal serogroup C-CRM(197) conjugate vaccine, provincial immunization records were linked with hospital discharge records, and medical charts were reviewed. In t
Autor:
Philippe De Wals, Gaston De Serres, Nicole Boulianne, Brigitte Lefebvre, Geneviève Deceuninck
Publikováno v:
The Pediatric infectious disease journal. 30(7)
A mass immunization campaign was implemented in 2001 to control a serogroup C meningococcal disease outbreak, and a newly licensed serogroup C meningococcal conjugate vaccine (C-MCV) was used. In 2002, 1 C-MCV dose was routinely offered to children 1
Autor:
Philippe De Wals
Publikováno v:
Vaccine. 27:5730
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
MacNeil JR, Medah I, Koussoubé D, Novak RT, Cohn AC, Diomandé FV, Yelbeogo D, Kambou JL, Tarbangdo TF, Ouédraogo-Traoré R, Sangaré L, Hatcher C, Vuong J, Mayer LW, Djingarey MH, Clark TA, Messonnier NE
Publikováno v:
Emerging infectious diseases [Emerg Infect Dis] 2014 Mar; Vol. 20 (3), pp. 394-9.